Inogen Stock Price, News & Analysis (NASDAQ:INGN)

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" INGN shares.
View INGN analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued twelve-month price objectives for Inogen's stock. Their INGN share price targets range from $7.00 to $26.00. On average, they expect the company's stock price to reach $13.67 in the next year. This suggests a possible upside of 135.2% from the stock's current price.
View analysts price targets for INGN or view top-rated stocks among Wall Street analysts.

Inogen's stock was trading at $19.71 on January 1st, 2023. Since then, INGN shares have decreased by 70.5% and is now trading at $5.81.
View the best growth stocks for 2023 here.

Inogen saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,550,000 shares, an increase of 52.0% from the October 31st total of 1,020,000 shares. Based on an average trading volume of 277,700 shares, the short-interest ratio is presently 5.6 days.
View Inogen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our INGN earnings forecast.

Inogen, Inc. (NASDAQ:INGN) announced its quarterly earnings data on Tuesday, November, 7th. The medical technology company reported ($1.97) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $1.41. The medical technology company earned $84 million during the quarter, compared to the consensus estimate of $82.09 million. Inogen had a negative net margin of 40.42% and a negative trailing twelve-month return on equity of 30.65%. The firm's revenue was down 20.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.34) EPS.

Inogen updated its FY 2023 earnings guidance on Tuesday, September, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $315.00 million-$320.00 million, compared to the consensus revenue estimate of $316.73 million.

70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Inogen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (4.59%), Ameriprise Financial Inc. (2.88%), AQR Capital Management LLC (2.62%), Meros Investment Management LP (2.54%), Kent Lake Capital LLC (1.99%) and Jacobs Levy Equity Management Inc. (1.71%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends.

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.